Sandra Esq - Bristol Myers Exec Counsel
| BMYB34 Stock | BRL 355.25 12.45 3.63% |
Insider
Sandra Esq is Exec Counsel of Bristol Myers Squibb
| Age | 62 |
| Phone | 212 546 4000 |
| Web | https://www.bms.com |
Bristol Myers Management Efficiency
The company has return on total asset (ROA) of 0.0613 % which means that it generated a profit of $0.0613 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1846 %, meaning that it generated $0.1846 on every $100 dollars invested by stockholders. Bristol Myers' management efficiency ratios could be used to measure how well Bristol Myers manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Zachary Sopcak | UnitedHealth Group Incorporated | N/A | |
| Peter Ewens | T Mobile | 60 | |
| Kim Goodman | Charter Communications | 53 | |
| Jay Carlson | Charter Communications | N/A | |
| Jud Henry | T Mobile | N/A | |
| Philipp Kuckuck | MAHLE Metal Leve | N/A | |
| Janice Kapner | T Mobile | N/A | |
| Mauricio Ramos | Charter Communications | 50 | |
| Yan Zeng | Autohome | 55 | |
| Jonathan Hargis | Charter Communications | 62 | |
| Cliff Hagan | Charter Communications | 58 | |
| Craig Jacobson | Charter Communications | 66 | |
| John Rex | UnitedHealth Group Incorporated | 61 | |
| Abdul Saad | T Mobile | N/A | |
| Tom Montemagno | Charter Communications | 52 | |
| Peter Osvaldik | T Mobile | 46 | |
| Chengbei Tian | Autohome | N/A | |
| Daniel Alves | MAHLE Metal Leve | N/A | |
| Brian Thompson | UnitedHealth Group Incorporated | N/A | |
| David Merritt | Charter Communications | 64 | |
| Anita Chen | Autohome | N/A | |
Management Performance
| Return On Equity | 0.18 | |||
| Return On Asset | 0.0613 |
Bristol Myers Squibb Leadership Team
Elected by the shareholders, the Bristol Myers' board of directors comprises two types of representatives: Bristol Myers inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bristol. The board's role is to monitor Bristol Myers' management team and ensure that shareholders' interests are well served. Bristol Myers' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bristol Myers' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jitendra Tyagi, Head India | ||
| Cari Gallman, VP Officer | ||
| David Elkins, Ex CFO | ||
| BCH BM, Ex Devel | ||
| Giovanni MD, Chairman CEO | ||
| Greg Meyers, Ex Officer | ||
| Ann Judge, Senior Vice President - Global Human Resources | ||
| Sandra Esq, Exec Counsel | ||
| Timothy Power, VP Relations | ||
| Christopher Boerner, Executive Vice President and Chief Commercial Officer |
Bristol Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bristol Myers a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.18 | |||
| Return On Asset | 0.0613 | |||
| Profit Margin | 0.14 % | |||
| Operating Margin | 0.20 % | |||
| Current Valuation | 1.04 T | |||
| Shares Outstanding | 2.13 B | |||
| Price To Earning | 50.79 X | |||
| Price To Book | 5.00 X | |||
| Price To Sales | 18.62 X | |||
| Revenue | 46.16 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Bristol Stock
When determining whether Bristol Myers Squibb offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bristol Myers' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bristol Myers Squibb Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bristol Myers Squibb Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.